FDA Brief

Warning letters Drugs

FDA warning letter to

Covalent Medical

MediumIssued Jul 9, 2025Posted Jul 15, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Covalent Medical that its FOCUS PI post-injection eye drops are an unapproved new drug with claims not allowed for over-the-counter eye products.

What happened

FDA reviewed the company's product labeling, website (focusvitamins.com) and Instagram and Facebook pages on September 27, 2024; there was no inspection. The agency found the eye drops promoted for relief of irritation after eye injections, a use not permitted under the over-the-counter (OTC) monograph, the FDA rulebook for nonprescription drug classes. FDA said the product is therefore an unapproved new drug and is misbranded (mislabeled in the legal sense).

What FDA found

  1. The company sold the eye drops as a nonprescription drug without an FDA-approved application and without meeting the OTC monograph for eye products.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. The label, website and social media claimed relief of irritation after eye injections, which the OTC ophthalmic monograph does not allow for lubricant eye drops.

    Section 505G of the FD&C Act, 21 U.S.C. 355h; OTC Monograph M018
  3. The product is legally misbranded because it is a nonprescription drug that does not meet the requirements for marketing under section 505G and has no approved application.

    Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA asks the company to write to CDER's Office of Unapproved Drugs and Labeling Compliance within 15 working days describing the steps taken to correct the violations and prevent repeat, with supporting documents; if more time is needed, the company must say why and give a completion date.

Who should pay attention

  • ophthalmology and eye care practices that recommend or stock the product
  • OTC eye drop brands that make drug-like claims online
  • retailers and distributors selling unapproved eye care products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk